Compugen employed its proprietary computational discovery platform to identify new drug targets with the ability to enhance anti-cancer immune responses and selected the COM503 anti IL-18BP antibody aimed for the treatment of solid tumors. The gene discussed is IL18BP; the disease is cancer.